Unmasking a sustained negative effect of SGLT2 inhibition on body fluid volume in the rat

被引:48
|
作者
Masuda, Takahiro [1 ]
Watanabe, Yuko [1 ]
Fukuda, Keiko [1 ]
Watanabe, Minami [1 ]
Onishi, Akira [1 ]
Ohara, Ken [1 ]
Imai, Toshimi [1 ]
Koepsell, Hermann [2 ]
Muto, Shigeaki [1 ]
Vallon, Volker [3 ,4 ,5 ]
Nagata, Daisuke [1 ]
机构
[1] Jichi Med Univ, Dept Internal Med, Div Nephrol, Shimotsuke, Tochigi 3290498, Japan
[2] Univ Wurzburg, Dept Mol Plant Physiol & Biophys, Julius von Sachs Inst, Wurzburg, Germany
[3] Univ Calif San Diego, Dept Med, Div Nephrol & Hypertens, San Diego, CA 92103 USA
[4] Univ Calif San Diego, Dept Pharmacol, Div Nephrol & Hypertens, San Diego, CA 92103 USA
[5] VA San Diego Healthcare Syst, San Diego, CA USA
关键词
bioimpedance analysis; body fluid volume; diuresis; natriuresis; SGLT2; inhibition; COTRANSPORTER; 2; INHIBITOR; TYPE-2; DIABETES-MELLITUS; SALT-SENSITIVE HYPERTENSION; RENAL GLUCOSE REABSORPTION; GLOMERULAR HYPERFILTRATION; BLOOD-PRESSURE; PROXIMAL TUBULE; PLASMA-VOLUME; AKITA MICE; OBESE RATS;
D O I
10.1152/ajprenal.00143.2018
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
The chronic intrinsic diuretic and natriuretic tone of sodium-glucose cotransporter 2 (SGLT2) inhibitors is incompletely understood because their effect on body fluid volume (BFV) has not been fully evaluated and because they often increase food and fluid intake at the same time. Here we first compared the effect of the SGLT2 inhibitor ipragliflozin (Ipra, 0.01% in diet for 8 wk) and vehicle (Veh) in Spontaneously Diabetic Torii rat, a nonobese type 2 diabetic model, and nondiabetic Sprague-Dawley rats. In nondiabetic rats, Ipra increased urinary excretion of Na+ (UNaV) and fluid (UV) associated with increased food and fluid intake. Diabetes increased these four parameters, but Ipra had no further effect, probably because of its antihyperglycemic effect, such that glucosuria and, as a consequence, food and fluid intake were unchanged. Fluid balance and BFV, determined by bioimpedance spectroscopy, were similar among the four groups. To study the impact of food and fluid intake, nondiabetic rats were treated for 7 days with Veh, Ipra, or Ipra+pair feeding+pair drinking (Pair-Ipra). Pair-Ipra maintained a small increase in UV and UNaV versus Veh despite similar food and fluid intake. Pair-Ipra induced a negative fluid balance and decreased BFV, whereas Ipra or Veh had no significant effect compared with basal values. In conclusion, SGLT2 inhibition induces a sustained diuretic and natriuretic tone. Homeostatic mechanisms are activated to stabilize BFV, including compensatory increases in fluid and food intake.
引用
收藏
页码:F653 / F664
页数:12
相关论文
共 50 条
  • [1] SGLT2 inhibition and kidney protection
    Nespoux, Josselin
    Vallon, Volker
    CLINICAL SCIENCE, 2018, 132 (12) : 1329 - 1339
  • [2] Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume
    Masuda, Takahiro
    Muto, Shigeaki
    Fukuda, Keiko
    Watanabe, Minami
    Ohara, Ken
    Koepsell, Hermann
    Vallon, Volker
    Nagata, Daisuke
    PHYSIOLOGICAL REPORTS, 2020, 8 (02):
  • [3] The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease
    Ohara, Ken
    Masuda, Takahiro
    Morinari, Masato
    Okada, Mari
    Miki, Atsushi
    Nakagawa, Saki
    Murakami, Takuya
    Oka, Kentaro
    Asakura, Maki
    Miyazawa, Yasuharu
    Maeshima, Akito
    Akimoto, Tetsu
    Saito, Osamu
    Nagata, Daisuke
    DIABETOLOGY & METABOLIC SYNDROME, 2020, 12 (01):
  • [4] Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
    Vallon, Volker
    Thomson, Scott C.
    DIABETOLOGIA, 2017, 60 (02) : 215 - 225
  • [5] Does SGLT2 Inhibition Affect Sympathetic Nerve Activity in Type 2 Diabetes?
    Dimova, Rumyana
    Tankova, Tsvetalina
    HORMONE AND METABOLIC RESEARCH, 2021, 53 (02) : 75 - 84
  • [6] Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition
    Herat, Lakshini Y.
    Matthews, Jennifer
    Azzam, Omar
    Schlaich, Markus P.
    Matthews, Vance B.
    CURRENT HYPERTENSION REPORTS, 2022, 24 (03) : 67 - 74
  • [7] The Pathophysiological Basis of Diabetic Kidney Protection by Inhibition of SGLT2 and SGLT1
    Oe, Yuji
    Vallon, Volker
    KIDNEY AND DIALYSIS, 2022, 2 (02): : 349 - 368
  • [8] SGLT2 inhibition and glucagon secretion in humans
    Saponaro, C.
    Pattou, F.
    Bonner, C.
    DIABETES & METABOLISM, 2018, 44 (05) : 383 - 385
  • [9] Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure
    Scheen, Andre J.
    CURRENT CARDIOLOGY REPORTS, 2019, 21 (08)
  • [10] Renoprotective Effects of SGLT2 Inhibitors: Beyond Glucose Reabsorption Inhibition
    Tsimihodimos, V.
    Filippatos, T. D.
    Filippas-Ntekouan, S.
    Elisaf, M.
    CURRENT VASCULAR PHARMACOLOGY, 2017, 15 (02) : 96 - 102